Avacta Group (DB:RTQ1) - Hisse Senedi Fiyatı, Haberler ve Analizler

RTQ1 Stoklara Genel Bakış

Avacta Group Plc, Birleşik Krallık, Fransa, Kuzey Amerika, Güney Kore, Avrupa'nın geri kalanı ve uluslararası alanda kanser ilaçları ve in vitro diagnostikler geliştirmektedir.

Şirket hakkında

RTQ1 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Gelirin yılda 14.32% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 0.4% oranında düşmesi öngörülüyor

1 yıldan az nakit akışı var

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Avacta Group Plc Rakipler

2invest

XTRA:2INV

€59.2m

Heidelberg Pharma

XTRA:HPHA

€116.5m

Formycon

XTRA:FYB

€863.4m

Biotest

XTRA:BIO3

€1.3b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Avacta Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£0.57
52 Haftanın En Yüksek Seviyesi	UK£1.78
52 Haftanın En Düşük Seviyesi	UK£0.41
Beta	1.12
11 Aylık Değişim	5.56%
3 Aylık Değişim	-22.45%
1 Yıllık Değişim	-61.75%
33 Yıllık Değişim	-54.03%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-63.81%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	RTQ1	DE Biotechs	DE Pazar
7D	-8.8%	-3.1%	-1.0%
1Y	-61.7%	-15.2%	16.1%

Getiri vs. Endüstri: RTQ1 geçen yıl % -15.2 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: RTQ1 geçen yıl % 16.1 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is RTQ1's price volatile compared to industry and market?
RTQ1 volatility
RTQ1 Average Weekly Movement	16.6%
Biotechs Industry Average Movement	6.1%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: RTQ1 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: RTQ1 'nin haftalık oynaklığı ( 17% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2003	154	Chris Coughlin	www.avacta.com

Avacta Group Plc, Birleşik Krallık, Fransa, Kuzey Amerika, Güney Kore, Avrupa'nın geri kalanı ve uluslararası alanda kanser ilaçları ve in vitro diagnostikler geliştirmektedir. Şirket, Teşhis ve Terapötikler segmentleri aracılığıyla faaliyet göstermektedir. Çeşitli pazarlara hitap eden farklılaştırılmış terapötik ve tanısal ürünlerden oluşan bir portföy sunmak için kullanılan tescilli Affimer ve pre|CISION teknoloji platformlarını sunmaktadır.

Avacta Group Plc Temel Bilgiler Özeti

Avacta Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
RTQ1 temel i̇stati̇sti̇kler
Piyasa değeri	€231.59m
Kazançlar(TTM)	-€30.92m
Gelir(TTM)	€27.01m

8.6x

P/S Oranı

-7.5x

F/K Oranı

RTQ1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
RTQ1 gelir tablosu (TTM)
Gelir	UK£22.62m
Gelir Maliyeti	UK£13.10m
Brüt Kâr	UK£9.52m
Diğer Giderler	UK£35.40m
Kazançlar	-UK£25.89m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.071
Brüt Marj	42.08%
Net Kâr Marjı	-114.45%
Borç/Özkaynak Oranı	49.8%

RTQ1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

RTQ1 Stoklara Genel Bakış

Ödüller

Risk Analizi

Avacta Group Plc Rakipler

XTRA:2INV

€59.2m

XTRA:HPHA

€116.5m

XTRA:FYB

€863.4m

XTRA:BIO3

€1.3b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

New major risk - Financial position

Recent updates

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform

Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium

First half 2024 earnings released: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)

New major risk - Financial position

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group plc Announces Board Changes

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Full year 2023 earnings released: UK£0.091 loss per share (vs UK£0.15 loss in FY 2022)

New minor risk - Financial data availability

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.036 loss in 1H 2022)

New major risk - Financial position

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

New major risk - Share price stability

New major risk - Share price stability

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Full year 2022 earnings released: UK£0.15 loss per share (vs UK£0.11 loss in FY 2021)

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

High number of new and inexperienced directors

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

First half 2022 earnings released: UK£0.036 loss per share (vs UK£0.041 loss in 1H 2021)

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

High number of new and inexperienced directors

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Less than half of directors are independent

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.084 loss in FY 2020)

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.037 loss in 1H 2020)